However, among the KRAS-mutated NSCLC, a KRAS G12C mutation has been identified in 30% to 50% of cases and currently represents the only targetable mutation associated with different clinical trials or allowing the treatment of patients with one of the KRAS G12C inhibitors (sotorasib), which has been recently approved by the FDA/EMA for second line treatment based on phase II results (CodeBreak 100 clinical trial) [23,25,26,28,29,30]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.